MENLO PARK, Calif.--(BUSINESS WIRE)--Optivia Biotechnology Inc. announced today the appointment of Dr. Jean-Michel Scherrmann to the Company's Scientific Advisory Board (SAB). Dr. Scherrmann is a preeminent scientist with expertise in drug transporters in neuropharmacokinetics and drug delivery strategies to the brain.
Dr. Scherrmann currently serves as a professor in the Department of Pharmacokinetics, Faculty of Pharmacy, at the University Paris Descartes. Dr. Scherrmann previously led the Neuropsychopharmacology Unit at the French Institute of Health and Medical Research (INSERM) and the National Center for Scientific Research (CNRS). Dr. Scherrmann has made major contributions to the development of drug radioimmunoassays, drug detoxification by immunotherapy, and drug redistribution concepts in pharmacokinetics.
"This is an exciting time for Optivia with its many promising discoveries in transporter biology yet to be discovered," said Dr. Scherrmann. "I am excited to join a team with such a strong scientific and technology position. I look forward to being a part of their success."
Dr. Yong Huang, Optivia’s president and CEO, said, "We are delighted to have Dr. Scherrmann join Optivia’s Scientific Advisory Board. Dr. Scherrmann will play an instrumental role in our efforts to target transporters for improving drug delivery across Blood-Brain-Barrier - a major bottleneck in Central Nervous System drug development."
Optivia’s SAB includes prominent scientists representing a range of disciplines including pharmacokinetics, biopharmaceutics, and transporter biology. The SAB will be an ongoing resource to provide Optivia’s management with counsel and guidance relating to the research, development, and application of Optivia’s Transporter Assay Portfolio and technologies.
About Transporter Proteins
Transporters are a class of 300 to 400 membrane proteins that act as nature’s “gatekeepers,” facilitating the movement of drugs, nutrients, and other bioactive molecules into and out of cells. As such, transporters play a vital role in drug response and safety, and they can be therapeutic targets for various diseases such as Central Nervous System (CNS) disorders, cancer, and diabetes.
About Optivia Biotechnology
Since bringing the first full panel of FDA- and EMA- compliant transporter drug-drug interaction (DDI) assays to market, Optivia has been the leading provider of high-quality transporter assay services. Optivia is a thought leader in expanding the utility of transporter research in areas as diverse as pharmacokinetics, toxicology, therapeutic target discovery, and basic biology research. With the world’s largest portfolio of transporter assays, novel multi-transporter models, and customized molecular transport research solutions, Optivia is committed to understanding the complex drug transport processes for improving drug safety and efficacy.